Senolytics in Kidney Aging: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Kidney aging is characterized by progressive structural and functional decline, contributing to increased susceptibility to chronic kidney disease (CKD), acute kidney injury, and systemic morbidity in the elderly. Cellular senescence marked by irreversible growth arrest, resistance to apoptosis, and the development of a pro-inflammatory senescence-associated secretory phenotype (SASP) plays a pivotal role in driving renal aging and pathology. Senolytic agents, which selectively eliminate senescent cells, have emerged as a promising therapeutic strategy to mitigate age-associated kidney dysfunction. This review synthesizes recent advances in the understanding of senescence in renal aging, evaluates the clinical and experimental evidence for senolytic interventions, and discusses their potential integration into nephrological practice, with a focus on safety, efficacy, and guideline-based recommendations.

Introduction

The global demographic trend towards an aging population has underscored the importance of understanding the mechanisms underpinning organ senescence, particularly in the kidney. Renal aging is associated with glomerulosclerosis, tubular atrophy, interstitial fibrosis, and a decline in glomerular filtration rate (GFR), all of which contribute to the onset and progression of CKD. Cellular senescence, a hallmark of tissue aging, not only impairs renal regenerative capacity but also perpetuates inflammation through the SASP, further exacerbating tissue damage. This review explores the epidemiology, pathophysiology, risk factors, clinical phenotypes, and current diagnostic and therapeutic approaches in kidney aging, with a special emphasis on the translational promise of senolytic therapies.

Epidemiology / Disease Burden

Renal aging is a significant contributor to the rising burden of CKD worldwide. Epidemiological studies show that the prevalence of CKD increases markedly with age, affecting over 30% of individuals above 70 years. Age-related decline in renal function is compounded by comorbid conditions such as hypertension, diabetes, and cardiovascular disease. With advancing age, the risk of end-stage renal disease (ESRD) and associated mortality also rises, posing substantial challenges to healthcare systems. The identification of modifiable factors in kidney aging and the development of targeted interventions remain pressing clinical priorities.

Pathophysiology

The pathophysiology of kidney aging centers on the accumulation of senescent cells within the renal parenchyma. Cellular senescence is triggered by telomere attrition, DNA damage, oxidative stress, mitochondrial dysfunction, and chronic inflammation. Senescent renal epithelial, endothelial, and fibroblast cells adopt a SASP, secreting pro-inflammatory cytokines, chemokines, matrix metalloproteinases, and growth factors. This pro-inflammatory milieu drives tissue remodeling, fibrosis, and impaired nephron function. Additionally, the decreased regenerative capacity of the aged kidney results from stem/progenitor cell exhaustion and senescence-induced paracrine effects on neighboring cells, establishing a self-perpetuating cycle of damage and dysfunction.

Risk Factors

Multiple factors accelerate kidney aging and the accumulation of senescent cells. These include genetic predisposition, chronic exposure to nephrotoxins, hypertension, hyperglycemia, metabolic syndrome, and persistent low-grade inflammation. Lifestyle factors such as poor diet, sedentary behavior, and smoking further contribute to oxidative stress and cellular damage. Importantly, iatrogenic factors such as repeated episodes of acute kidney injury, nephrotoxic medications, and suboptimal control of comorbid condition may hasten renal senescence.

Clinical Features

Clinically, kidney aging manifests as a progressive decline in GFR, impaired sodium and water handling, reduced concentrating ability, and increased proteinuria. Elderly patients are more vulnerable to dehydration, electrolyte imbalances, drug toxicity, and rapid progression to CKD or ESRD. Histologically, aged kidneys exhibit glomerular basement membrane thickening, arteriolosclerosis, tubular dropout, and interstitial fibrosis. These structural changes correlate with functional decline and underpin the increased risk of renal and systemic complications in the elderly.

Diagnosis

Diagnosis of kidney aging relies on a combination of clinical assessment, laboratory evaluation, and imaging studies. Key diagnostic parameters include estimation of GFR (using creatinine or cystatin C-based equations), assessment of proteinuria, and imaging evidence of kidney size, cortical thickness, and parenchymal echogenicity. Recent advancements in biomarkers such as urinary KIM-1, NGAL, and senescence-associated β-galactosidase activity offer promise for the early detection and monitoring of renal senescence. However, standardized clinical assays for senescent cell burden are not yet routinely available.

Treatment & Management

Current management of kidney aging focuses on mitigating risk factors, optimizing control of blood pressure and glycemia, minimizing nephrotoxin exposure, and addressing comorbidities. Lifestyle modifications including dietary sodium restriction, increased physical activity, and smoking cessation are recommended. Pharmacologic interventions may include renin-angiotensin-aldosterone system (RAAS) blockade and statins. However, these measures primarily slow progression rather than reverse established senescence-driven damage. As such, there is an unmet need for therapies that target the fundamental mechanisms of renal aging.

Recent Advances / Emerging Therapies

Senolytic agents have emerged as a transformative approach in the management of organ aging, including the kidney. Compounds such as dasatinib, quercetin, fisetin, and navitoclax selectively induce apoptosis in senescent cells by inhibiting pro-survival pathways. Preclinical studies demonstrate that senolytics reduce renal fibrosis, improve function, and restore regenerative capacity in aged murine models. Early-phase clinical trials are exploring the safety and efficacy of these agents in human populations, with encouraging initial results. Combination therapies targeting both senescent cells and SASP components may further enhance outcomes. Nevertheless, potential off-target effects and optimal dosing regimens remain active areas of investigation.

Guideline Recommendations

Current nephrology guidelines recognize the importance of addressing senescence as a pathogenic driver in kidney aging. While lifestyle modification and risk factor control remain first-line, expert consensus supports the inclusion of senolytic therapies within the context of clinical trials or compassionate use protocols for high-risk elderly patients. Ongoing trials are expected to inform future guideline updates, particularly regarding patient selection, safety monitoring, and integration with standard-of-care therapies. Multidisciplinary collaboration between nephrologists, geriatricians, and translational scientists is essential to optimize the therapeutic potential of senolytics.

Conclusion

Renal aging is a complex, multifactorial process underpinned by the accumulation of senescent cells and SASP-driven tissue remodeling. Senolytic agents offer a novel, mechanism-based strategy to rejuvenate the aging kidney, with promising results in preclinical and early clinical studies. As research progresses, careful assessment of efficacy, safety, and guideline-based integration will be critical to realizing the clinical promise of senolytics in kidney aging. Continued interdisciplinary efforts and robust clinical trials are imperative to advance the management of renal aging and improve outcomes for the growing elderly population.